ERYTECH announces the approval of the merger with Pherecydes and communicates the results of the Combined General Meeting of June 23, 2023
All resolutions were passed by a large majority in accordance with the recommendations of the Board of Directors.
The company is renamed Phaxiam Therapeutics, creating a world leader in phage therapy.
Lyon (France), June 23, 2023 – ERYTECH Pharma (Euronext Paris & Nasdaq: ERYP) announces today that all resolutions for which the Board of Directors recommended a favorable vote, including the approval of the merger with Pherecydes , were adopted by its shareholders at the Combined General Meeting (AGM) held today, June 23, 2023.